Drugs Containing Excipient (Inactive Ingredient) AMMONIUM METHACRYLATE

Ammonio Methacrylate Copolymer Market Dynamics and Financial Trajectory

Last updated: November 1, 2026

Ammonium methacrylate is not generally marketed as a standalone pharmaceutical excipient. The relevant pharmaceutical material is ammonio methacrylate copolymer, a family of pH-independent, water-permeable coating polymers used in modified-release tablets, capsules, pellets and multiparticulate systems. Evonik Industries is the principal global supplier through its EUDRAGIT RL and EUDRAGIT RS product families. The market is a specialty excipient segment tied to oral controlled-release dosage forms, generic reformulation activity and contract development manufacturing.

Public companies do not report revenue for ammonio methacrylate copolymer separately. Financial performance is therefore assessed through end-market demand, supplier concentration, regulatory barriers, product mix and pricing rather than a verified standalone market-size series.

What is ammonio methacrylate copolymer used for in pharmaceuticals?

Ammonio methacrylate copolymer controls drug release by forming a permeable polymer membrane around an active pharmaceutical ingredient. The polymer contains quaternary ammonium groups that remain ionized across the gastrointestinal pH range. Water penetrates the coating, dissolves the drug and permits controlled diffusion through the film.

The main applications are:

Application	Function	Typical dosage forms
Sustained release	Reduces release rate over several hours	Tablets, capsules, pellets
Extended release	Maintains plasma exposure and reduces dosing frequency	Matrix or reservoir systems
Multiparticulate delivery	Applies different coating levels to pellets or granules	Capsules, sachets, compressed multiparticulates
Taste masking	Limits immediate contact between drug and taste receptors	Granules, chewable products
Combination release profiles	Combines fast-release and coated fractions	Tablets and capsules

The most established commercial distinction is between higher-permeability and lower-permeability grades. EUDRAGIT RL polymers generally contain more quaternary ammonium functionality and produce greater water permeability than EUDRAGIT RS grades. Formulators adjust release by changing coating weight, plasticizer content, pore-former concentration, particle size and polymer combinations (Evonik Industries, n.d.-a).

Which pharmaceutical products contain ammonio methacrylate copolymer?

The excipient is used across generic and branded modified-release products, but public product labels do not always identify the specific polymer grade. The same active ingredient may use different coating systems in different markets.

Common product categories include:

Modified-release analgesics
Extended-release cardiovascular medicines
Oral antidiabetic products
Gastrointestinal medicines
Central nervous system therapies
Potassium and electrolyte preparations
Multiparticulate pediatric formulations
Generic products using reservoir-coated pellets

The commercial opportunity is strongest where a drug requires release-rate control but does not require a highly complex osmotic or biologic delivery platform. Ammonio methacrylate copolymers are particularly relevant to products seeking a robust, pH-independent release profile at moderate formulation cost.

What is the regulatory status of ammonio methacrylate copolymer?

Ammonio methacrylate copolymer is an established pharmaceutical excipient in the United States and Europe.

United States

The FDA Inactive Ingredient Database lists ammonio methacrylate copolymer as an inactive ingredient for oral dosage forms. The database is used by sponsors to assess prior exposure and route-specific precedent, although an entry does not constitute blanket approval for every dose, formulation or patient population (U.S. Food and Drug Administration, n.d.-a).

The excipient is not an active pharmaceutical ingredient and does not receive standalone New Drug Application approval. Its acceptability is evaluated within the finished drug application. Sponsors must control:

Polymer grade
Molecular-weight distribution
Quaternary ammonium content
Residual monomers
Solvent residues
Heavy metals and elemental impurities
Microbial quality
Film-coating process parameters

Europe

Ammonio methacrylate copolymers are recognized in European pharmaceutical practice and are associated with Ph. Eur. excipient specifications and supplier technical documentation. Marketing authorization holders must establish suitability under the finished-product quality dossier and comply with European requirements for excipient risk management and good manufacturing practice (European Commission, 2015).

Regulatory risk

The main regulatory risk is not basic acceptance of the polymer. It is manufacturing consistency and control of residual substances. Changes to monomer ratios, particle size, dispersion form, coating process or supplier can affect dissolution and may trigger regulatory variation requirements.

What patents protect ammonio methacrylate copolymer products?

The foundational intellectual property covering the broad concept of ammonio methacrylate copolymers and their use in pharmaceutical film coatings is largely mature. The principal commercial differentiator is now manufacturing know-how, specification control, regulatory history and customer qualification.

Relevant patent categories include:

Patent category	Commercial relevance	Current risk
Polymer composition	Defines monomer ratios or functional-group content	Foundational claims are generally mature
Pharmaceutical coating process	Covers coating conditions, solvent systems or curing	Can remain relevant to specific products
Drug-polymer formulation	Protects a particular active ingredient and release profile	Important in branded and complex generic products
Multiparticulate architecture	Protects pellet layering, coating sequences or release combinations	Can create product-specific barriers
Manufacturing process	Covers dispersion, polymerization or purification	Supplier know-how may be more important than public patent claims
Product branding	Protects names such as EUDRAGIT	Trademark protection remains commercially important

There is no Orange Book listing for ammonio methacrylate copolymer itself. The FDA Orange Book lists approved drug products, patents and exclusivity associated with active pharmaceutical products, not standalone excipients (U.S. Food and Drug Administration, n.d.-b).

A drug sponsor using the polymer may hold method-of-use or formulation patents that cover a finished dosage form. Those patents would attach to the drug product, not to the excipient as a general material. A Paragraph IV challenge would therefore target the listed drug's patents and would not ordinarily challenge the excipient directly.

When does ammonio methacrylate copolymer lose exclusivity?

The excipient does not have a single regulatory exclusivity date. It is not protected by pharmaceutical market exclusivity in the way an active drug is.

The practical exclusivity position is as follows:

Asset	Exclusivity position
Basic polymer chemistry	Generally available to qualified manufacturers
EUDRAGIT trade names	Controlled by trademark ownership
Supplier specifications	Protected through know-how and confidential quality systems
Finished-drug formulation	May remain protected by drug patents
Coating process	May be protected by patents, trade secrets or both
Regulatory history	Creates switching friction but not legal exclusivity

Competitors can theoretically develop equivalent copolymers. In practice, substitution requires comparative dissolution data, stability testing, process revalidation, supplier audits and potentially regulatory filings. This gives established suppliers commercial protection even where broad composition patents are no longer blocking.

How strong is the patent estate for ammonio methacrylate copolymer?

The patent estate is moderate at the material level and stronger at the application level.

At the material level, the product is a mature polymer platform with multiple possible manufacturers and no standalone Orange Book exclusivity. At the application level, a formulation using the polymer may have meaningful protection if the patent claims a specific release profile, coating architecture, particle design or combination therapy.

The strongest barriers are usually:

Proprietary manufacturing consistency
Validated dissolution performance
Customer-specific regulatory files
Long-term supply qualification
Finished-drug formulation patents
Process knowledge for aqueous or organic coating systems

This structure reduces the probability that a low-cost polymer entrant can immediately displace an incumbent in an approved product.

How many companies manufacture ammonio methacrylate copolymer?

Evonik is the most visible global supplier through the EUDRAGIT brand. Other excipient and polymer manufacturers may offer functionally similar materials, but public commercial data do not establish a complete global supplier count.

Evonik Industries

Evonik supplies EUDRAGIT RL and RS polymers in multiple forms, including solid resins and aqueous dispersions. Its competitive position comes from a broad pharmaceutical excipient portfolio, technical support, established regulatory documentation and extensive use in approved oral dosage forms (Evonik Industries, n.d.-a; Evonik Industries, n.d.-b).

Alternative suppliers

Alternative sources may exist in China, India and other manufacturing regions, particularly for generic formulations and development-stage products. Their market access is limited by:

Need for equivalence data
Customer qualification requirements
Regulatory documentation
Scale-up performance
Batch-to-batch dissolution reproducibility
Global GMP audit expectations

The market is therefore supplier-concentrated even though the chemistry itself is not necessarily protected by an effective monopoly.

What drives demand for ammonio methacrylate copolymer?

Demand is driven by oral modified-release development rather than by a single therapeutic area.

Generic drug development

Generic manufacturers use established coating polymers to reproduce reference-product dissolution profiles. Demand rises when high-value immediate-release products are reformulated into extended-release or multiparticulate versions, or when generic sponsors need a reliable platform for complex oral dosage forms.

Lifecycle management

Innovator and specialty pharmaceutical companies use modified-release systems to extend product differentiation, reduce dosing frequency or improve tolerability. Ammonio methacrylate copolymers can support these programs without the infrastructure required for biologic delivery systems.

Contract development and manufacturing

CDMOs increasingly develop controlled-release products for multiple sponsors. This creates recurring demand for validated excipients, especially where the CDMO standardizes a polymer platform across projects.

Patient and formulation requirements

Multiparticulate systems are relevant to pediatric, geriatric and dysphagia-focused products. Taste masking and flexible release profiles support liquid-filled capsules, granules and sprinkle formulations.

What is the financial trajectory of the ammonio methacrylate copolymer market?

No audited public financial series isolates ammonio methacrylate copolymer revenue. The likely trajectory is steady growth with price segmentation rather than rapid expansion.

Period	Expected market condition	Financial implication
Near term	Stable demand from generic and modified-release products	Recurring base business
Medium term	Growth in complex generics and multiparticulates	Higher-value technical sales
Longer term	Greater competition from alternative polymers and local suppliers	Price pressure on standard grades
Across all periods	Qualification and regulatory switching costs	Retention of incumbent accounts

Revenue quality is stronger for specialty grades, aqueous dispersions and technical-service packages than for commodity polymer resins. Suppliers that provide formulation support, dissolution modeling, regulatory packages and scale-up assistance can maintain better margins.

The principal financial risks are:

Generic pricing pressure
Customer consolidation
Regional competition from lower-cost suppliers
Raw-material cost volatility
Regulatory delays for alternate sources
Substitution by other controlled-release polymers
Loss of a major drug product customer after patent expiry

The principal growth opportunities are:

Complex generic formulations
Pediatric multiparticulates
Higher-performance aqueous systems
Combination of ammonio methacrylate copolymer with other release-control polymers
Expansion in India, China and other generic manufacturing centers
CDMO platform adoption

How does ammonio methacrylate copolymer compare with competing excipients?

Excipient platform	Main strength	Main limitation	Relative position
Ammonio methacrylate copolymer	pH-independent permeable film	Requires coating-process control	Strong for reservoir and multiparticulate systems
Ethylcellulose	Robust water-insoluble barrier	Often needs pore formers or blends	Strong alternative for sustained release
Hypromellose	Broad availability and matrix functionality	Release can vary with hydration and food effects	Strong for hydrophilic matrix tablets
Cellulose acetate	Useful in membrane and osmotic systems	More process-specific	Strong in specialized delivery systems
Polyvinyl acetate-based systems	Flexible matrix and coating use	Different release mechanism and processing profile	Competitive in selected products
Methacrylic acid copolymers	Enteric or pH-triggered release	Not generally pH-independent	Complementary rather than direct substitute

The choice depends on whether the sponsor needs pH-independent permeability, an insoluble barrier, a hydrophilic matrix or enteric release. Ammonio methacrylate copolymer is strongest where the formulation requires controlled diffusion through a polymer film.

What manufacturing and intellectual-property barriers affect market entry?

Manufacturing barriers are more important than broad composition patents.

A credible entrant must demonstrate:

Controlled copolymer composition
Reproducible quaternary ammonium content
Low residual monomer levels
Stable particle-size distribution
Consistent film formation
Comparable permeability
Reproducible dissolution after storage
Pharmaceutical GMP compliance
Reliable global supply

A substitute may pass chemical testing and still fail as a commercial replacement if it produces a different release profile during coating, compression or scale-up. This creates a high switching threshold for approved products.

Geographically, European and U.S. customers generally place greater weight on regulatory documentation and supplier audit history. Indian and Chinese generic manufacturers may be more receptive to qualified regional suppliers when cost savings offset technical and filing burdens.

What generic entry risks exist for drugs using ammonio methacrylate copolymer?

The excipient generally lowers formulation risk because it is established and widely understood. It does not eliminate generic entry risk.

For a finished drug, the key issues are:

Whether the reference product uses a protected release mechanism
Whether formulation patents claim the coating architecture
Whether dissolution can be matched across multiple media
Whether a Paragraph IV certification targets remaining patents
Whether the generic sponsor has access to qualified polymer supply
Whether supplier changes require regulatory notification

A generic entrant can use the same polymer, a different grade or an alternative excipient. The legal analysis depends on the finished product's listed patents, not on the generic availability of ammonio methacrylate copolymer.

What is the commercial outlook for ammonio methacrylate copolymer?

The outlook is positive but mature. Volume should track oral modified-release and complex generic activity. Margin expansion is more likely in specialty grades, technical support and regulatory services than in standard polymer sales.

The market is unlikely to produce standalone blockbuster economics. Its value is strategic: the polymer supports a broad installed base of controlled-release products and creates recurring demand from drug developers, generic manufacturers and CDMOs. Supplier strength will depend on quality consistency, documentation, technical service and the ability to support global regulatory filings.

Key Takeaways

The relevant pharmaceutical material is ammonio methacrylate copolymer, not usually standalone ammonium methacrylate.
Evonik's EUDRAGIT RL and RS families are the most visible commercial products.
The polymer is used mainly in pH-independent sustained-release and multiparticulate formulations.
There is no standalone Orange Book exclusivity or drug-style regulatory exclusivity for the excipient.
Foundational composition protection is mature; application patents and manufacturing know-how remain more relevant.
Public companies do not disclose a separate revenue line for this excipient.
Market growth is tied to complex generics, oral modified release, CDMO activity and pediatric multiparticulates.
The main commercial moat is qualification, regulatory history and manufacturing consistency.
Generic entry risk attaches to finished-drug patents and dissolution performance, not to the excipient in isolation.
The financial profile is a stable specialty-excipient business with moderate growth and increasing regional price competition.

FAQs About Ammonio Methacrylate Copolymer

Is ammonio methacrylate copolymer safe for oral pharmaceutical use?

It is an established oral pharmaceutical excipient when used within approved formulation specifications and controlled for residual monomers, impurities and manufacturing consistency.

Is EUDRAGIT RS the same as ammonio methacrylate copolymer?

EUDRAGIT RS is a branded grade within the ammonio methacrylate copolymer family. Its lower permeability distinguishes it from higher-permeability RL grades.

Can a drug manufacturer replace EUDRAGIT with another polymer?

Yes, but replacement requires formulation development, comparative dissolution testing, stability data, supplier qualification and assessment of regulatory filing requirements.

Does ammonio methacrylate copolymer have an FDA monograph?

The material is recognized through inactive-ingredient and pharmacopeial frameworks, but it does not receive standalone FDA approval in the same way as an active drug. Its acceptability is assessed within the finished product application.

Is ammonio methacrylate copolymer a threat to biologic drug delivery systems?

It is primarily a conventional oral dosage-form excipient. It may compete with other oral controlled-release technologies, but it is not a direct substitute for most injectable, implantable or biologic delivery systems.

References

European Commission. (2015). Guidelines on the formalised risk assessment for ascertaining the appropriate good manufacturing practice for excipients of medicinal products for human use. European Commission.

Evonik Industries. (n.d.-a). EUDRAGIT functional polymers for pharmaceutical applications. Evonik Industries AG.

Evonik Industries. (n.d.-b). EUDRAGIT RL and EUDRAGIT RS technical information. Evonik Industries AG.

U.S. Food and Drug Administration. (n.d.-a). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm

More… ↓

⤷ Start Trial